The Business Research Company’s report on the Vitreoretinal Disorder Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the vitreoretinal disorder market in recent years?
The growing incidence of diabetic retinopathy is expected to propel the growth of the vitreoretinal disorder market going forward. Diabetic retinopathy is an eye condition that occurs due to damage to the blood vessels in the retina caused by high blood sugar levels in people with diabetes. The incidence of diabetic retinopathy is increasing due to the rising prevalence of diabetes, driven by sedentary lifestyles, and poor blood sugar control, causing damage to retinal blood vessels. Vitreoretinal disorder management plays a crucial role in treating diabetic retinopathy by addressing complications such as vitreous hemorrhage and tractional retinal detachment, thereby preserving vision and preventing further retinal damage. For instance, in October 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022–23, 1.8% of screened First Nations people in Australia received treatment for diabetic retinopathy, with a lower age-standardized treatment rate (1.3%) than non-Indigenous Australians (1.5%). Therefore, the growing incidence of diabetic retinopathy is driving the growth of the vitreoretinal disorder market.
Access Your Free Sample of the Global Vitreoretinal Disorder Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=23574&type=smp
What is the projected market size of the vitreoretinal disorder industry, and how is it expected to grow?
The vitreoretinal disorder market size has grown strongly in recent years. It will grow from $4.30 billion in 2024 to $4.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the increasing prevalence of diabetic retinopathy, aging population growth, rising awareness of retinal diseases, expansion of healthcare infrastructure, and early adoption of anti-vascular endothelial growth factor (VEGF) therapy.
The vitreoretinal disorder market size is expected to see strong growth in the next few years. It will grow to $6.30 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to rising prevalence of age-related macular degeneration, increasing incidence of diabetic retinopathy, rising investment in regenerative stem cell therapies, increasing healthcare expenditure on eye diseases, rising awareness about early retinal disease detection, and government initiatives. Major trends in the forecast period include artificial intelligence (AI)-powered retinal disease detection, robotic-assisted vitreoretinal surgeries, nanotechnology-based drug delivery, smart contact lenses for real-time eye monitoring, ultra-high-resolution adaptive optics imaging, and biodegradable intravitreal implants.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=23574&type=smp
Who are the key players driving competition in the vitreoretinal disorder market?
Major companies operating in the vitreoretinal disorder market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Baxter International, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Alcon Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd. , Topcon Corporation, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, EyePoint Pharmaceuticals Inc., Kodiak Sciences Inc., Clearside Biomedical.
What key trends are expected to drive the visceral leishmaniasis market during the forecast period?
Major companies operating in the vitreoretinal disorder market are focusing on developing innovative solutions, such as methotrexate for treating primary vitreoretinal lymphoma, to address the unmet medical needs associated with rare and aggressive retinal cancers. Methotrexate for treating primary vitreoretinal lymphoma refers to the intravitreal use of a chemotherapy drug to target and suppress cancerous cells in the retina and vitreous, offering a localized and effective treatment for this rare eye cancer. For instance, in December 2022, Aldeyra Therapeutics Inc., a US-based biotechnology company, announced a positive pre-NDA meeting with the FDA regarding ADX-2191, a novel, preservative-free formulation of methotrexate for treating primary vitreoretinal lymphoma (PVRL), a rare and aggressive retinal cancer.
Which key geographies are driving the growth of the vitreoretinal disorder market?
North America was the largest region in the vitreoretinal disorder market in 2024. The regions covered in the vitreoretinal disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/vitreoretinal-disorder-global-market-report
What are the key segments driving growth in the vitreoretinal disorder market?
The vitreoretinal disorder market covered in this report is segmented –
1) By Type: Retinal Tear, Retinal Detachment, Diabetic Retinopathy, Macular Degeneration, Macular Hole, Other Types
2) By Diagnosis: Digital Fluorescein Angiography, Optical Coherence Tomography, Heidelberg Retinal Tomography, Indocyanine Green Angiography, Other Diagnosis
3) By Treatment: Surgery, Medication, Other Treatments
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Retinal Tear: Atrophic Retinal Tear, Operculated Retinal Tear, Horseshoe Retinal Tear, Giant Retinal Tear
2) By Retinal Detachment: Rhegmatogenous Retinal Detachment, Tractional Retinal Detachment, Exudative Retinal Detachment
3) By Diabetic Retinopathy: Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
4) By Macular Degeneration: Dry Macular Degeneration, Wet Macular Degeneration
5) By Macular Hole: Full-Thickness Macular Hole, Lamellar Macular Hole, Tractional Macular Hole
6) By Other Types: Epiretinal Membrane, Retinal Vein Occlusion, Retinal Artery Occlusion, Retinitis Pigmentosa, Uveitis, Vitreous Hemorrhage, Macular Edema, Central Serous Retinopathy, Proliferative Vitreoretinopathy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23574
How is the vitreoretinal disorder market defined, and what are its core characteristics?
Vitreoretinal disorder refers to a group of eye conditions that affect the retina and the vitreous humor, which plays a crucial role in maintaining the eye’s shape and visual clarity. These disorders can significantly impair vision over time and often require advanced diagnostic techniques and specialized medical or surgical interventions for effective management.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
